Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price

Simply Wall St · 05/10 12:28

Anika Therapeutics, Inc.'s (NASDAQ:ANIK) price-to-sales (or "P/S") ratio of 1.4x might make it look like a strong buy right now compared to the Biotechs industry in the United States, where around half of the companies have P/S ratios above 7.6x and even P/S above 44x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Check out our latest analysis for Anika Therapeutics

ps-multiple-vs-industry
NasdaqGS:ANIK Price to Sales Ratio vs Industry May 10th 2025

What Does Anika Therapeutics' Recent Performance Look Like?

While the industry has experienced revenue growth lately, Anika Therapeutics' revenue has gone into reverse gear, which is not great. It seems that many are expecting the poor revenue performance to persist, which has repressed the P/S ratio. So while you could say the stock is cheap, investors will be looking for improvement before they see it as good value.

Keen to find out how analysts think Anika Therapeutics' future stacks up against the industry? In that case, our free report is a great place to start.

What Are Revenue Growth Metrics Telling Us About The Low P/S?

The only time you'd be truly comfortable seeing a P/S as depressed as Anika Therapeutics' is when the company's growth is on track to lag the industry decidedly.

In reviewing the last year of financials, we were disheartened to see the company's revenues fell to the tune of 31%. This means it has also seen a slide in revenue over the longer-term as revenue is down 22% in total over the last three years. Accordingly, shareholders would have felt downbeat about the medium-term rates of revenue growth.

Turning to the outlook, the next year should bring diminished returns, with revenue decreasing 2.5% as estimated by the three analysts watching the company. Meanwhile, the broader industry is forecast to expand by 175%, which paints a poor picture.

With this information, we are not surprised that Anika Therapeutics is trading at a P/S lower than the industry. However, shrinking revenues are unlikely to lead to a stable P/S over the longer term. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.

The Final Word

Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

With revenue forecasts that are inferior to the rest of the industry, it's no surprise that Anika Therapeutics' P/S is on the lower end of the spectrum. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. Unless there's material change, it's hard to envision a situation where the stock price will rise drastically.

Many other vital risk factors can be found on the company's balance sheet. Take a look at our free balance sheet analysis for Anika Therapeutics with six simple checks on some of these key factors.

If these risks are making you reconsider your opinion on Anika Therapeutics, explore our interactive list of high quality stocks to get an idea of what else is out there.